These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28049880)

  • 1. [Pharmacological and clinical profile of a novel dual endothelin receptor antagonist, macitentan (Opsumit
    Takahashi S; Horie R; Yokoyama Y
    Nihon Yakurigaku Zasshi; 2017; 149(1):49-58. PubMed ID: 28049880
    [No Abstract]   [Full Text] [Related]  

  • 2. Macitentan: A Review in Pulmonary Arterial Hypertension.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
    Angus JA; Soeding PF; Hughes RJA; Wright CE
    Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Discovery of Macitentan - A Standard Medicinal Chemistry Program?
    Bolli MH
    Chimia (Aarau); 2017 Aug; 71(7):420-429. PubMed ID: 28779766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macitentan (Opsumit) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
    Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
    Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macitentan for the treatment of pulmonary arterial hypertension.
    Sood N
    Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
    Dhillon S
    Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
    Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macitentan: first global approval.
    Patel T; McKeage K
    Drugs; 2014 Jan; 74(1):127-33. PubMed ID: 24297706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
    McCoy EK; Lisenby KM
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
    Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macitentan for the treatment of pulmonary arterial hypertension.
    Kholdani CA; Fares WH; Trow TK
    Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macitentan approved by FDA to delay progression of PAH.
    Thompson CA
    Am J Health Syst Pharm; 2013 Dec; 70(23):2054. PubMed ID: 24249746
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of Macitentan in Fontan circulation: a case report.
    Demetriades P; Aziz A; Condliffe R; Bowater SE; Clift PF
    BMC Cardiovasc Disord; 2017 May; 17(1):131. PubMed ID: 28532389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.